Related Experiment Videos
Vitronectin in atherosclerotic disease.
Ozlem Balci Ekmekçi1, Hakan Ekmekçi
1Istanbul University, Istanbul Medical Faculty, Department of Pediatric Heamatology/Oncology, Bone Marrow Transplantation Unit, Istanbul, Turkey.
Clinica Chimica Acta; International Journal of Clinical Chemistry
|February 8, 2006
Summary
Vitronectin, a plasma glycoprotein, plays a key role in atherosclerosis development. Its ability to bind platelets contributes to vascular injury and the progression of coronary atherosclerosis.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Pathophysiology
Background:
- Atherosclerosis involves intimal thickening with immune cells, smooth muscle cells, lipids, and extracellular matrix.
- Vitronectin is a plasma glycoprotein regulating coagulation, fibrinolysis, immune responses, and cell adhesion.
- Vitronectin binds platelet glycoproteins, mediating adhesion and aggregation at vascular injury sites.
Purpose of the Study:
- To elucidate the role of vitronectin in the pathogenesis of coronary atherosclerosis.
Main Methods:
- Literature review and analysis of existing research on vitronectin and atherosclerosis.
Main Results:
- Vitronectin's interaction with platelets is crucial for its role in vascular injury.
- Vitronectin acts as a significant mediator in the development of coronary atherosclerosis.
Conclusions:
- Vitronectin is an important factor in the pathogenesis of coronary atherosclerosis due to its platelet-binding properties.